Troponin T, High Sensitivity (hs-TnT)

Cleveland Heartlab T, Test

NEW YORK DOH APPROVED: NO

CPT Code: 84484
Order Code: 38685
ABN Requirement: No
Synonyms: hs-cTnT; Cardiac Troponin T
Specimen
: Plasma
Volume:  1.0 mL
Minimum Volume:  0.5 mL
Container: Lithium Heparin (Green Top) tube

Collection:

  1. Draw and gently invert green top tube 8-10 times immediately after draw.
  2. Centrifuge for 10 minutes.
  3. Pre-squeeze transfer pipet bulb and draw off approximately 2/3 of the upper plasma layer.
    Note: This ensures that the buffy coat and red cells remain undisturbed.
  4. Aliquot plasma into transport tube labeled as “Lithium Heparin Plasma” and cap tightly. Discard original tube.
  5. Store transport tube refrigerated at 2-8°C until ready to ship.

Transport: Store lithium heparin plasma at 2°C to 8°C after collection and ship the same day per packaging instructions included with the provided shipping box.

Stability:

Ambient (15-25°C): Not Acceptable
Refrigerated (2-8°C):
7 days
Frozen (-20°C):
12 months

Causes for Rejection: Specimens other than lithium heparin plasma; improper labeling; samples not stored properly; samples older than stability limits; hemolysis; gross icterus; gross lipemia

Methodology: Electrochemiluminescence Immunoassay (ECLIA)

Turn Around Time: 5 days

Relative Risk Ranges:

SexLow Risk
ng/L
Moderate Risk
ng/L


High Risk
ng/L
Female<66-14>14
Male<66-22>22

Priority Values:

SexPriority 1 Values (ng/L)

Female>14
Male>22

Clinical Significance: High sensitivity Troponin T (hs-TnT) is an independent prognostic marker that aids in the diagnosis of myocardial infarction (MI) in an acute setting and there is literature supporting its use to identify relative risk of cardiovascular disease (CVD).

Limitations: Samples should not be taken from patients receiving therapy with high biotin doses (i.e. >5 mg/day) until at least 8 hours following the last biotin administration. There is no high-dose hook effect at Troponin T concentrations up to 100,000 ng/L. For assays using antibodies, the possibility exists for interference by heterophile antibodies in the patient’s sample. Patients who have been regularly exposed to animals or have received immunotherapy or diagnostic procedures using immunoglobulin or immunoglobulin fragments may produce antibodies, e.g. HAMA, that interfere with immunoassays. Carefully evaluate the results of patients suspected of having these antibodies. In rare cases, interference due to extremely high titers of antibodies to analyte-specific antibodies, streptavidin or ruthenium can occur. The reagent has been formulated to minimize this effect.

The CPT codes provided are based on AMA guidelines and are for informational purposes only. CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payer being billed.